High risk of non-cancer mortality in bladder cancer patients: evidence from SEER-Medicaid

被引:3
|
作者
Wang, Shunde [1 ]
Ge, Chengguo [2 ]
机构
[1] ChenJiaqiao Hosp ShaPingba Dist Chongqing City, Dept Urol, Chongqing 401331, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 2, Dept Urol, 76 Linjiang Rd, Chongqing 400010, Peoples R China
关键词
Bladder cancer; Standardized mortality ratio; Non-cancer cause of death; Competing risk analysis; SEER; DEATH; CHEMOTHERAPY;
D O I
10.1007/s00432-023-04867-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe objective of this study was to investigate non-cancer causes of death and associated risk factors after bladder cancer (BC) diagnosis.MethodsEligible BC patients were obtained from the SEER database. SEER*Stat software 8.3.9.2 was used to calculate the standardized mortality ratios (SMRs). The proportions of different non-cancer cause of death were calculated and analyzed in different follow-up periods. Multivariate competing risk model was used to analyze the risk factors for death of BC and non-cancer diseases.ResultsIn total, 240,954 BC patients were included and 106,092 patients experienced death, with 37,205 (35.07%), 13,208 (12.45%) and 55,679 (52.48%) patients experienced BC, other cancer and non-cancer disease-related deaths, respectively. Overall SMR for BC patients who died from non-cancer diseases was 2.42 (95% CI [2.40-2.44]). Cardiovascular diseases were the most common non-cancer cause of death, followed by respiratory diseases, diabetes mellitus, and infectious diseases. Multivariate competing risk analysis identified the following high-risk factors for non-cancer mortality: age > 60 years, male, whites, in situ stage, pathological type of transitional cell carcinoma, not receiving treatment (including surgery, chemotherapy, or radiation), and widowed.ConclusionsCardiovascular diseases are the leading non-cancer cause of death in BC patients, followed by respiratory disease, diabetes mellitus and infectious diseases. Physicians should pay attention to the risk of death from these non-cancer diseases. Also, physicians should encourage patients to engage in more proactive self-surveillance and follow up.
引用
收藏
页码:10203 / 10215
页数:13
相关论文
共 50 条
  • [31] Immediate risk of non-cancer deaths after a cancer diagnosis
    Yang, Pengcheng
    Zheng, Yongqiang
    Chen, Jiayuan
    Ma, Haotian
    Yu, Kaixu
    Chen, Ying
    Yang, Yun
    Wu, Bian
    BMC CANCER, 2021, 21 (01)
  • [32] Immediate risk of non-cancer deaths after a cancer diagnosis
    Pengcheng Yang
    Yongqiang Zheng
    Jiayuan Chen
    Haotian Ma
    Kaixu Yu
    Ying Chen
    Yun Yang
    Bian Wu
    BMC Cancer, 21
  • [33] Cardiovascular Mortality Risk among Patients with Liver Cancer: A SEER Database Study
    Li, Juan
    Zhang, Junyong
    He, Song
    CURRENT CANCER DRUG TARGETS, 2024,
  • [35] Cancer and Non-Cancer Risk Concerns from Metals in Electronic Cigarette Liquids and Aerosols
    Fowles, Jefferson
    Barreau, Tracy
    Wu, Nerissa
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (06)
  • [36] COMPARISON OF CANCER-SPECIFIC SURVIVAL AND NON-CANCER SURVIVAL AMONG PATIENTS WITH GASTROINTESTINAL AND LUNG NEUROENDOCRINE TUMORS - A SEER STUDY
    Kang, Dasol
    Yoon, Ji Yoon
    Yang, Jeong Yun
    Kim, Michelle K.
    GASTROENTEROLOGY, 2021, 160 (06) : S608 - S608
  • [37] Comparing mortality between cancer and non-cancer critically ill patients: A propensity score matched analysis
    Rosa R.
    Duso B.
    Mattioni M.
    Rosa M.D.
    Ascoli A.M.
    Maccari J.
    Tonietto T.
    Barth J.H.
    Morandi P.
    Dexheimer F.
    Rutzen W.
    Madeira L.
    Tagliari L.
    Oliveira R.P.D.
    Teixeira C.
    Intensive Care Medicine Experimental, 3 (Suppl 1)
  • [38] A probabilistic framework for non-cancer risk assessment
    Chen, James J.
    Moon, Hojin
    Kodell, Ralph L.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2007, 48 (01) : 45 - 50
  • [39] Cardiovascular mortality by cancer risk stratification in patients with localized prostate cancer: a SEER-based study
    Luo, Zehao
    Chi, Kaiyi
    Zhao, Hongjun
    Liu, Linglong
    Yang, Wenting
    Luo, Zhijuan
    Liang, Yinglan
    Zeng, Liangjia
    Zhou, Ruoyun
    Feng, Manting
    Li, Yemin
    Hua, Guangyao
    Rao, Huying
    Lin, Xiaozhen
    Yi, Min
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [40] Concurrent Gabapentin and Opioid Use and Risk of Mortality in Medicare Recipients with Non-Cancer Pain
    Corriere, Meghan A.
    Daniel, Laura L.
    Dickson, Alyson L.
    Nepal, Puran
    Hall, Kathi
    Plummer, W. Dale
    Dupont, William D.
    Murray, Katherine T.
    Stein, C. Michael
    Ray, Wayne A.
    Chung, Cecilia P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (05) : 1050 - 1057